US FDA awards Supplemental Orphan Drug Designation to SurVaxM to now include treatment of Malignant Glioma
US FDA awards Supplemental Orphan Drug Designation to SurVaxM to now include treatment of Malignant Glioma
MimiVax Announces New Investments to Support Clinical Development of SurVaxM in Glioblastoma
Investors feature leading brain tumor venture philanthropy funds including the Brain Tumor Investment Fund (BTIF) and the Sontag Innovation Fund, along with MEDA Angels, Varia Ventures and private investors. Investment…
White arrow breaking the wall and passing to the other side.
MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma
MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma
Providing hope through unique immunotherapy
MimiVax Announces Positive Final Data from the Phase IIa Study of SurVaxM for Newly Diagnosed Glioblastoma Published Today in the Journal of Clinical Oncology
Buffalo, NY. December 15, 2022 - MimiVax is pleased to announce the published manuscript of the now completed Phase IIa study of SurVaxM, a cancer vaccine, in newly diagnosed glioblastoma (nGBM) in…
Phase 2a Trial of SurVaxM Plus Temozolomide for Newly Diagnosed Glioblastoma
SurVaxM appeared to be safe and well-tolerated in pts with nGBM. SurVaxM was effective at stimulating survivin-specific immune responses and the primary endpoint was met.
Roswell Park Opens Phase 2B Randomized Clinical Trial of Promising Brain Cancer Immunotherapy
First center to treat newly diagnosed glioblastoma patients as part of late-stage trial with SurVaxM BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center is the first center to treat patients…
Cape Egmont Lighthouse and Taranaki Mount on background, New Zealand
MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma
November 12, 2021 - MimiVax has received a “Study May Proceed” notification from the US FDA to initiate a Phase 2b clinical trial of SurVaxM in newly diagnosed glioblastoma -Completed Phase…
Brain cancer awareness, grey ribbon on helping hand
MimiVax Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM
https://www.prweb.com/releases/roswell_park_spinoff_company_advances_toward_new_clinical_trial_for_brain_cancer_immunotherapy_survaxm/prweb16737735.htm MimiVax LLC and Roswell Park to launch large clinical trial at centers in U.S. & abroad following major licensing deal MimiVax LLC secures $10 million upfront in licensing dealLarge…
MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China
Buffalo-based clinical-stage biotechnology company MimiVax, a Roswell Park Comprehensive Cancer Center spinoff, set to work with leading healthcare group in China to provide promising immunotherapy BUFFALO, N.Y. and SHANGHAI, Nov. 18, 2019 /PRNewswire/ --…
George Washington University Researchers presenting at 2019 MGFA Scientific Session, AANEM Annual Meeting
Linda Kusner, PhD will present new data utilizing MV2C2 antibodies in Myasthenia Gravis. “Survivin is a negative regulator of apoptosis in myasthenia gravis: a human and animal model study” (October 16,…